Chemical modifications to nucleosomal DNA and histone tails greatly influence transcription of adjacent and distant genes, a mode of gene regulation referred to as epigenetic control. Here, the authors summarize recent findings that have illustrated crucial roles for epigenetic regulatory enzymes and reader proteins in the control of cardiac fibrosis. Particular emphasis is placed on epigenetic regulation of stress-induced inflammation and fibroblast activation in the heart.
C ardiac fibrosis may be beneficial, replacing regions of myocyte loss with a structural scar following myocardial infarction (MI), or maladaptive, involving excessive extracellular matrix (ECM) deposition in response to long-standing stress (1) . Unrestrained cardiac fibrosis can elicit various deleterious effects. For example, interstitial fibrosis increases the passive stiffness of the myocardium, contributing to diastolic dysfunction (2, 3) , and disrupts electrical conduction in the heart, causing arrhythmias and sudden cardiac death (4) . Unfortunately, despite the widely accepted roles of fibrosis in cardiac dysfunction, no targeted antifibrotic drugs for the heart currently exist.
A growing body of evidence suggests that "epige- Histone acetyltransferases (HATs) catalyze the addition of acetyl groups to lysine residues in histone tails. HATs are divided into 2 typical families, Gcn5 and MYST, named for their founding members (8) .
Other proteins, such as p300/CBP, Taf1, and nuclear receptor coactivators also have catalytic acetyltransferase activities; however, they do not contain true consensus HAT domains and are categorized as an orphan class. The enzymes that remove acetyl groups from histone tails are histone deacetylases An emerging role for BRD4 is in the formation of large, dynamic, cell state-specific enhancers, referred to as super-enhancers (SEs) (13, 14) . As discussed in the following text, BRD4 plays a central role in the control of cardiac fibrosis, in part through its ability to enhance the formation of SEs (15) . Additional reader domains for acetyl-histone (e.g., YEATs), as well as readers of other histone marks such as methylation, have been described (16 Cardiac fibrosis is a complex, multifactorial process (25, 26) . For the purposes of this review, rather than simply listing epigenetic events that contribute to fibrosis of the heart, we describe roles of epigenetic regulatory effectors within the framework of distinct, but overlapping, phases of the fibrotic response: inflammation and fibroblast activation (Central Illustration).
EPIGENETICS IN INFLAMMATION EPIGENETIC CONTROL OF INFLAMMATION.
Inflammation has long been recognized as an important component of heart failure pathogenesis (27) . It is thought that cardiac stress (e.g., MI) leads to nuclear factor-kB (NF-kB)-mediated stimulation of cytokine/ chemokine gene expression in resident cardiac cells In response to pathological stresses such as myocardial infarction (MI) or pressure overload, epigenetic machinery is activated to promote cardiac inflammation and cardiac fibroblast proliferation, leading to cardiac fibrosis. Complex interplay between histone deacetylase (HDAC), histone acetyltransferase (HAT), lysine methyltransferase (KMT), lysine demethylase (KDM), DNA methyltransferase (DNMT), and ten-eleven translocation (TET) enzymes governs acetylation (Ac) of histones and methylation (Me) of histones and DNA that make up nucleosomes. antiproliferative genes and genes that normally repress myofibroblast differentiation.
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Epigenetics in Cardiac Fibrosis molecule BET bromodomain inhibition was shown to potently suppress a network of cardiac NF-kBresponsive genes that control the innate immune response (53) . Mechanistically, the BET family member BRD4 directly interacts with NF-kB through acetylated Lys310 of the p65 subunit, an interaction that is required for NF-kB transactivation ( Figure 1A) (54). In a genome-wide study employing TNF-astimulated endothelial cells, acetylated p65 was also shown to establish new SEs proximal to genes governing the canonical inflammatory response, and BET inhibition blocked NF-kB-directed SE reorganization (55) . Future studies will determine whether a similar BRD4-dependent mechanism controls cardiac inflammation and fibrosis.
EPIGENETIC CONTROL OF MACROPHAGES AND
TREGS. To our knowledge, no studies have addressed epigenetic mechanisms in specific inflammatory cell types in the context of cardiac disease, 
SAHA reduces IL-1a, IL2, and TNF-a expression in DOCA-salt hypertensive rats.
VPA treatment suppresses the M1 phenotype of cultured macrophages.
Class I HDAC inhibitors promote the M2 anti-inflammatory phenotype of macrophages.
(66-68)
Class IIa HDACs are positive regulators of the M1 proinflammatory phenotype.
(69-71)
BET reader BET inhibition potently suppresses a network of cardiac NF-kB responsive genes that control the innate immune response.
(53-55)
BET reader proteins play fundamental roles in regulating macrophage inflammatory phenotypes.
(74-76)
Histone methylation KMT1 represses proinflammatory genes associated with the M1 phenotype by promoting the formation of H3K9me3 marks on regulatory elements.
KMT3 negatively regulates the proinflammatory M1 phenotype by increasing repressive H3K36 dimethylation at promoter regions of proinflammatory genes.
KDM6 promotes the M1 macrophage phenotype by removing repressive H3K27 trimethylation marks at regulatory sites for proinflammatory genes.
DNA methylation In the setting of obesity and diabetes, DNMT1 promotes the M1 macrophage phenotype by hypermethylating of the pro-M2 transcription factor, PPARg1.
(63,64)
Fibroblast proliferation/ activation
Histone acetylation MGCD0103 potently suppresses cardiac fibroblast proliferation and mitigates fibrotic remodeling in response to cardiac injury.
(98-101)
Inhibition of the p300 HAT blocks the proliferative response of cardiac fibroblasts and suppresses Ang II-mediated cardiac fibrosis.
TSA blocks a-SMA expression in lung fibroblasts in association with reduced activation of AKT.
The balance of HAT and HDAC expression influences TGF-b-induced transcription of SM22a.
BET reader BET inhibitors block conversion of liver, pancreas and skin fibroblasts into a-SMA þ myofibroblasts.
( [109] [110] [111] In response to stress signaling, BRD4 accumulates on SEs for genes encoding secreted profibrotic factors such as TGF-b2.
Knockdown of JMJD1A increases expression of a-SMA.
KMT2H directly binds regulatory elements of profibrotic genes, including those encoding a-SMA.
DNA methylation
Knockdown of DNMT3B or treatment with the DNMT inhibitor blocks a-SMA expression.
Cardiac fibrosis correlates with enhanced DNA methylation of promoter sequences regulating the gene encoding RASAL1, a RAS-GTPaseactivating protein.
BET ¼ bromodomain and extraterminal protein; DNMT ¼ DNA methyltransferase; HDAC ¼ histone deacetylase; SAHA ¼ suberoylanilide hydroxamic acid; SE ¼ superenhancer; TSA ¼ trichostatin A; VPA ¼ valproic acid. In summary, this is an exquisitely exciting time for our field. Advances in the basic science of epigenetics, nonhistone epigenetic marks, and cardiac fibrosis promise to be rapidly forthcoming and to facilitate the clinical translation of innovative "epigenetic therapies" for patients who have heart disease.
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